Multiply Labs partners with AstraZeneca to automate cell therapy manufacturing

Multiply Labs said its modular approach to cell therapy automation reduces manufacturing bottlenecks. | Source: Multiply Labs

Multiply Labs Inc. today announced an agreement with AstraZeneca to evaluate the potential for applying good manufacturing practice, or GMP-ready, robotic systems to commercial-scale cell therapy manufacturing. The collaboration will focus on automation of industry-standard instruments used in cell therapy production using Multiply Labs’ robotic biomanufacturing system.